Blog

T cells

Autolomous and Vineti form strategic partnership to deliver end to end supply chain management solutions for cell and gene therapy sector

Autolomous LTD, the market leading developer of critical manufacturing management systems for cell and gene therapies, and Vineti, a provider of leading digital enterprise platforms for cell and gene therapy supply chains, today announce a non-exclusive collaborative partnership.

Read More
March 26, 2021

A new Five-minute Guide — seven key challenges in advanced therapy clinical trials

Advanced therapies emerge from advanced science — and must overcome the operational complexity inherent in their patient-centric paradigm when they...

March 25, 2021

Biopharmaceutical and technology leaders form collaboration to promote standards and a modern patient ID for advanced therapies

Genentech, Takeda, Adaptimmune and other industry leaders join Vineti to form the core of this strategic collaboration. The group is...

March 24, 2021

Repost: a modern patient ID for personalized medicine

Today, Vineti released an announcement about new industry collaboration around our proposal for a new patient ID for cell and gene therapies....

February 3, 2021

A fresh start for advanced therapy clinical trials

A look at 2020 and the coming rebound, by the numbers Even before the unpredictable year that was 2020, one...

January 11, 2021

Introducing new Vineti PTM® flexibility features: next-gen label printing and rescheduling innovations deliver critical workflow options that advanced therapies require

Introducing new Vineti PTM® flexibility features: next-gen label printing and rescheduling innovations deliver critical workflow options that advanced therapies require...

January 4, 2021

The Vineti Alliance Network — a preview of what’s next

For Vineti, 2020 has been all about continuing to deliver progress for advanced therapies, even amid an unpredictable year. One...

December 15, 2020

How PTM® Label Printing keeps every patient journey on track

In advanced therapies, little labels — the in-process labels on bags of cells and final drug products — can sometimes...

November 30, 2020

A true platform is the engine for advanced therapies

A Vineti technology perspective from Chief Technology Officer Phil Calvin Phil Calvin, Vineti’s Chief Technology Officer, is a long-time leader...

November 23, 2020

How digital solutions solve the “3D chess game” and drive Commercial success

A Vineti technology perspective from Chief Commercial Officer Joe DePinto Joe DePinto, Vineti’s Chief Commercial Officer, is a long-time leader...

November 17, 2020

A modern patient ID for personalized medicine

Patient-specific therapeutics must be delivered to the patient they are intended to treat. That concept is easy to say —...

November 17, 2020

Now is the time for proven technology that drives scale

A Vineti technology perspective from CEO and Co-founder Amy DuRoss   The underlying medical science behind cell and gene therapies continues...

October 13, 2020

Vineti Extends Series C Funding Round to $68M with an Expanded Investor Coalition

Today, we’re very excited and honored to announce the extension of our Series C round of funding. We’ve expanded the...